Tiny machines that rebuild themselves on demand

Reconfigurable structures that can repeatedly change their ...

‘What’s your weirdness?’ A winter day spent exploring that and many other fun questions at MIT’s museums.

Those of us disinclined to winter sports can still exercise our minds when it’s icy outside. We always feel at least ...
Ever After in the Woods

This Hidden Illinois State Park Lets You See Buffalo Up Close

Watch bison roam above the Illinois River at this scenic Illinois state park with bluff views, prairie trails, and a day trip ...

Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
Grazia Daily UK on MSN

Follow all the highlights from New York Fashion Week

Don’t underestimate New York Fashion Week. If the autumn/winter ’26 ...
Family Destinations Guide

The Mouth-Watering Burgers At This Tiny Restaurant Are Worth The Drive From Anywhere In Indiana

That moment happens every day at Miner-Dunn in Highland, Indiana. Driving along Indianapolis Boulevard, you might miss it if ...
Labmate Online

Virus-like particle vaccine has expanded rare HIV-targeting B cells in lab studies

Researchers at MIT and Scripps have reported that a DNA-based virus-like particle vaccine has generated markedly higher ...
Tech Xplore on MSN

Ultrafast 3D printing method creates complex objects in under a second

High-speed 3D printing has just gotten a lot faster. Researchers from Tsinghua University in China have developed a new high-speed printing technology capable of creating complex millimeter-scale ...
Le Lézard

RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...
PharmiWeb

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...